• LAST PRICE
    4.3200
  • TODAY'S CHANGE (%)
    Trending Up0.3500 (8.8161%)
  • Bid / Lots
    4.0800/ 2
  • Ask / Lots
    4.5000/ 2
  • Open / Previous Close
    3.9900 / 3.9700
  • Day Range
    Low 3.8900
    High 4.5400
  • 52 Week Range
    Low 3.6300
    High 13.4000
  • Volume
    263,972
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.97
TimeVolumeCELU
09:32 ET4383.91
09:33 ET12003.9012
09:35 ET16643.89
09:37 ET3003.96
09:44 ET3553.96
09:46 ET8003.93
09:50 ET6994
09:57 ET5003.9
10:08 ET1303.9136
10:11 ET5003.9419
10:13 ET1003.945
10:15 ET117123.96
10:24 ET127453.935
10:26 ET11503.935
10:29 ET12003.97
10:31 ET10003.97
10:33 ET26353.92
10:40 ET3003.94
10:44 ET6003.9219
10:45 ET2503.9664
10:51 ET5003.9283
10:58 ET1003.96
11:00 ET143593.99
11:02 ET7003.995
11:05 ET1004.01
11:12 ET1004.02
11:14 ET1004.02
11:16 ET28524.02
11:18 ET1004.02
11:20 ET1004.03
11:21 ET9094.02
11:23 ET4004.03
11:27 ET1004.03
11:30 ET36004.03
11:32 ET2004.1
11:36 ET2004.07
11:38 ET14004.03
11:39 ET4004.07
11:41 ET4024.1
11:45 ET3004.13
11:48 ET1004.14
11:50 ET10004.0799
11:52 ET2004.06
11:54 ET1004.1
11:56 ET2004.1
11:57 ET2994.0746
11:59 ET102354.13
12:01 ET56554.14
12:06 ET2004.21
12:10 ET2004.21
12:12 ET4044.15
12:14 ET5004.15
12:17 ET1004.17
12:19 ET1004.16
12:21 ET2004.17
12:24 ET49354.14
12:26 ET3004.16
12:32 ET5674.17
12:33 ET3004.22
12:37 ET1004.21
12:39 ET3004.21
12:44 ET2004.21
12:46 ET3004.23
12:50 ET1004.22
12:51 ET10004.16
12:53 ET1004.24
12:55 ET2004.22
01:02 ET4004.19
01:04 ET18004.22
01:06 ET1004.22
01:08 ET12004.18
01:09 ET4004.21
01:13 ET8004.21
01:22 ET7004.2
01:24 ET1004.21
01:26 ET2004.21
01:27 ET4004.1865
01:31 ET3004.22
01:33 ET16004.22
01:38 ET30434.2
01:40 ET10004.216
01:42 ET5004.22
01:44 ET5004.22
01:47 ET1004.26
01:49 ET2004.25
01:51 ET7614.27
01:54 ET17704.24
01:56 ET1004.25
01:58 ET1004.25
02:00 ET18104.2732
02:02 ET1004.28
02:03 ET1004.27
02:05 ET8694.27
02:09 ET2004.28
02:12 ET1004.28
02:14 ET170184.36
02:16 ET7004.3301
02:18 ET3004.3773
02:20 ET31694.47
02:21 ET131234.4201
02:23 ET15004.45
02:25 ET17474.47
02:27 ET3504.475
02:30 ET33694.48
02:32 ET43734.4854
02:34 ET16454.4383
02:38 ET72854.43
02:39 ET21314.41
02:41 ET8004.43
02:43 ET40154.49
02:45 ET5614.5
02:48 ET2004.475
02:50 ET5004.4694
02:52 ET4004.47
02:54 ET1004.49
02:56 ET11004.47
02:57 ET9004.47
02:59 ET12004.45
03:01 ET2004.455
03:03 ET1994.455
03:06 ET63444.46
03:08 ET11494.45
03:10 ET8104.42
03:12 ET38004.43
03:15 ET24284.36
03:17 ET52484.39
03:19 ET10064.38
03:21 ET13014.4
03:24 ET3004.39
03:26 ET5004.4
03:28 ET2004.3817
03:32 ET3004.4
03:33 ET5984.39
03:35 ET4704.334
03:39 ET2154.3533
03:42 ET28994.3689
03:46 ET8684.3632
03:48 ET10004.38
03:50 ET18324.35
03:51 ET65364.31
03:53 ET2384.3119
03:55 ET58134.315
03:57 ET37304.31
04:00 ET4794.32
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCELU
Celularity Inc
533.4M
14.7x
---
United StatesPNT
POINT Biopharma Global Inc
536.2M
0.0x
---
United StatesHUMA
Humacyte Inc
537.7M
-3.0x
---
United StatesALVR
Allovir Inc
528.3M
-3.6x
---
United StatesCGEM
Cullinan Oncology Inc
539.9M
-8.5x
---
United StatesOMIC
Singular Genomics Systems Inc
521.7M
0.0x
---
As of 2022-01-22

Company Information

Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic T cells engineered with a chimeric antigen receptor (CAR) (CAR-T) cells, natural killer (NK) cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, infectious and degenerative diseases. It has four placental-derived allogeneic cell types: T cells, unmodified NK cells, genetically modified NK cells and ASCs, which resulted in four key cell therapeutic programs: CyCART-19, CYNK-001, CYNK-101 and APPL-001, focused on six initial indications. Its CyCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the CD19 receptor. CYNK-001 is developing for the treatment of acute myeloid leukemia (AML), a blood cancer, and for glioblastoma multiforme (GBM), a solid tumor cancer, and COVID-19.

Contact Information

Headquarters
1325 AVENUE OF THE AMERICAS, 25TH FLOORNEW YORK, NY, United States 10019
Phone
212-616-3700
Fax
302-636-5454

Executives

No data available

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$533.4M
Revenue (TTM)
$0.00
Shares Outstanding
123.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$0.29
Book Value
$7.73
P/E Ratio
14.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.